Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Anthrax Vaccine Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for the anthrax vaccine has experienced robust expansion in the past few years. It is forecasted to increase from $11.27 billion in 2024 to $11.88 billion in 2025, with a compound annual growth rate (CAGR) of 5.4%. This significant growth during the historic period is influenced by factors such as fears of biological warfare, military requirements, occurrences of anthrax, preparation in public health sectors, and biodefense initiatives.

What Is the Forecast for the Anthrax Vaccine Market Size Through 2029?

Forecasted to experience robust growth in upcoming years, the anthrax vaccine market is projected to reach a worth of $14.5 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.1%. The expected escalation during the projection period is largely attributed to global security concerns, the emergence of new threats, and initiatives by the government for procurement. Also contributing to the growth during the forecast period is the pandemic readiness, a surge in government stockpiling, cooperation in research initiatives, and a stronger emphasis on next-generation vaccines. There will also be an increased accessibility in developing nations and innovative technological advancements in this period.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

What are the Key Market Players in Anthrax Vaccine Market and How They’re Evolving?

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

What Are the Primary Growth Drivers in the Anthrax Vaccine Market?

The escalation in the occurrence of infectious diseases is projected to catalyze the expansion of the anthrax vaccine market. Such diseases are caused by harmful microorganisms like bacteria, viruses, parasites, or fungi, which can be transmitted directly or indirectly, resulting in symptoms that can vary from mild to severe and can sometimes be lethal, contingent on the pathogen and the individual’s immune response. Factors like changes in the world’s population demographics, urbanization, environmental and land changes, and human behavior adjustments, contribute to the prevalence of infectious diseases. The anthrax vaccine is predominantly used to safeguard against anthrax while possibilities of its wider application in preventing other infectious diseases are being studied by examining its immune-response inducing properties and adaptability. For example, data from the Council on Foreign Relations, a US-based nonprofit organization, in February 2023, revealed that 75% of new or emergent infectious diseases and 60% of recognized infectious diseases stemmed from zoonotic origins. Moreover, zoonoses globally lead to 2.7 million human fatalities and 2.5 billion disease episodes in people annually. Thus, the escalating occurrence of diseases is propelling the anthrax vaccine market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp

What Are the Leading Segments in the Global Anthrax Vaccine Industry?

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

What Are the Key Market Trends in the Anthrax Vaccine Industry?

Major players in the anthrax vaccine market are striving to create innovative products and secure FDA authorization, ensuring their vaccines’ safety, efficacy, and accessibility to those vulnerable to anthrax. Approval by the FDA guarantees thorough testing of the vaccine in clinical trials, confirming its safe usage for the public, and offering protection against possible negative effects. For instance, in July 2023, the US-based biopharmaceutical firm, Emergent BioSolutions Inc., was granted approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly known as AV7909, by the U.S. Food and Drug Administration (FDA). This endorsement was based on data collected from a Phase 2 trial that examined Cyfendus’s non-conflict with antibacterial drugs, and Phase 3 clinical research that compared the vaccine’s immunogenicity and safety to BioThrax, the prior anthrax vaccine. Moreover, the creation of safer and more efficient adjuvants is crucial to solve issues related to reactogenicity and improve the overall performance of anthrax vaccines.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

What Is the Regional Outlook for the Anthrax Vaccine Market?

North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15511

This Report Delivers Insight On:

1. How big is the anthrax vaccine market, and how is it changing globally?

2. Who are the major companies in the anthrax vaccine market, and how are they performing?

3. What are the key opportunities and risks in the anthrax vaccine market right now?

4. Which products or customer segments are growing the most in the anthrax vaccine market?

5. What factors are helping or slowing down the growth of the anthrax vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model